This is our first report on SS&C Technologies, a well-known software solutions provider to the financial and healthcare industries. Despite the macroeconomic difficulties, SS&C’s business has remained strong though the company failed to meet Wall Street expectations in terms of revenues as well as earnings. The Alternatives business has given it a strong defense against market forces. Even while new fund launches and inflows influenced the Alternatives industry, it nevertheless developed well. GoCentral added new features, enabling more productivity in everyday operations and NABs and serving as a key point of differentiation in their sales strategy. Besides, DomaniRx can now be provided in a modular form supplied as different solutions, including finance, drug management, and communications hub, for existing SS&C health clients and prospects. This is because they have accelerated their go-to-market plans. Furthermore, despite a dip in fundraising after several years of increased activity, the company’s private markets increased by 15% in the second quarter. We believe that due to the breadth of their product offering, they are well-positioned to benefit from changing investment strategies. We initiate coverage on the stock of SS&C Technologies with a ‘Buy’ rating.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
Want unlimited access to our reports? Purchase our $99 annual subscription!